Caxton Associates (UK)’s BioNTech BNTX Stock Holding History

Caxton Associates (UK)’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,500	Closed	-$2.14M	–	794
2025 Q4	$2.14M	Buy	+22,500	New	+$2.27M	0.04%	178

Other funds holding BNTX

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Caxton Associates (UK)'s BNTX Position: Q1 2026 in Review

Caxton Associates (UK) sold out of BioNTech (BNTX) in Q1 2026, closing a stake of 22,500 shares — an estimated $2.14M sold.

Caxton Associates (UK) first reported a position in BNTX in Q4 2025 and held it in 1 quarter. The position peaked at $2.14M in Q4 2025. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

Caxton Associates (UK) reported no remaining BioNTech position as of Q1 2026 after selling out during the quarter.
Caxton Associates (UK) sold 22,500 BioNTech shares in Q1 2026, an estimated $2.14M.
Caxton Associates (UK) first reported a position in BioNTech in Q4 2025 and held it in 1 quarter.
Caxton Associates (UK)'s BioNTech position peaked at $2.14M in Q4 2025.
272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.